摘要
目的探讨局部外用噻吗洛尔滴眼液治疗浅表型婴幼儿血管瘤的疗效及安全性。方法将50例浅表型婴幼儿血管瘤患儿随机分为两组,每组各25例,试验组给予0.5%噻吗洛尔滴眼液30μL·cm^(-2),均匀涂于血管瘤的表面,每日2次;对照组给予5%咪喹莫特乳膏,均匀涂抹于血管瘤表面,每周3次,疗程均为3~6月。观察血管瘤颜色、厚度、面积变化并评分,记录不良反应发生情况,比较两组疗效。结果两组均完成24例。治疗后,试验组有效率为88%(21/24),对照组为71%(17/24),两组疗效比较差异显著(P<0.05)。试验组起效时间为(8.2±4.3)d,短于对照组[(12.3±5.2)d,P<0.05]。试验组病灶总评分为(5.7±1.2)分,对照组为(4.1±1.1)分,组间差异显著(P<0.05)。两组均未见明显不良反应发生。结论噻吗洛尔滴眼液治疗婴幼儿浅表型血管瘤的疗效好、安全性高,值得在临床推广应用。
AIM To explore the therapeutic effect and safety of topical application of timolol eye drops in the treatment of superficial infantile hemangiomas. METHODS Fifty enrolled infantile patients with superficial hemangioma were randomly divided into two groups, 25 patients in each group. The patients in the trial group were given 0.5% timolol eye drops 30 μL·cm-2 for external application, twice each day. The patients in the control group were given 5% imiquimod cream for external application, 3 times per week. The treatment course for the two groups was both three to six months. The color, thickness and area of the hemangioma were observed and graded. The adverse reaction was recorded and the efficacy of two groups was compared. RESULTS There were 24 patients completed the trial in each group. After the treatment, the effective rate was 88% （21/24） and 71% （17/24） in the trial group and control group. There was significant difference in therapeutic effect between two groups （P 〈 0.05）. Compared with that in the control group, the onset time in the trial group was shorter （12.3 ± 5.2） d vs. （8.2 ±4.3） d, P 〈 0.05）. And the focal total evaluation score in the trial group was higher than that in the control group （ （5.7 ±1.2） points vs. （4.1± 1.1） points, P 〈 0.05）. No obvious adverse reactions occurred in both groups. CONCLUSION Timolol eye drops has good effect and safety in treating infantile hemangioma, and can be widely used in clinic.
出处
《中国新药与临床杂志》
CAS
CSCD
北大核心
2016年第11期788-790,共3页
Chinese Journal of New Drugs and Clinical Remedies
关键词
血管瘤
儿童
噻吗洛尔
咪喹莫特
投药
皮肤
hemangioma
child
timolol
imiquimod
administration, cutaneous
